IPF & PPF     |     ENV-101     |     WHISTLE-PF TRIAL


Living with Idiopathic Pulmonary Fibrosis (IPF) or Progressive Pulmonary Fibrosis (PPF)?

A new clinical trial for individuals with pulmonary fibrosis

Idiopathic Pulmonary Fibrosis

Understanding Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

IPF and PPF are lung diseases that cause abnormal scarring in the lungs, leading to shortness of breath and persistent cough. These diseases can worsen over time, making it difficult for the lungs to absorb oxygen and ultimately impacting individuals' quality of life.

Current treatments may help slow the progress of IPF and PPF in some people, but they do not stop or reverse it. Individuals living with IPF and PPF may benefit from new treatment options that go beyond slowing disease progression to reverse lung fibrosis and improve lung function.

Introducing ENV-101

ENV-101 is an oral medicine being investigated by Endeavor BioMedicines, Inc., to treat fibrotic lung diseases, starting with IPF and PPF. ENV-101 blocks a protein in the body that is thought to be involved in lung scarring. Endeavor BioMedicines is evaluating whether ENV-101 may slow or reverse the disease and improve the symptoms of IPF and PPF.

Clinical Studies to Date
Endeavor BioMedicines recently evaluated ENV-101 in 21 patients with IPF. More information about this study is available at


Endeavor BioMedicines plans to initiate patient enrollment in a global trial designed to further evaluate the therapeutic potential of ENV-101 in individuals with IPF and PPF. The WHISTLE-PF clinical trial stands for Wound-remodeling Hedgehog-inhibitor ILD Study Testing Lung Function Endpoints. It is a Phase 2 trial evaluating the safety and efficacy of ENV-101.

Idiopathic Pulmonary Fibrosis

Endeavor BioMedicines:

Disrupting Disease, Restoring Hope

Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases.

Endeavor’s lead investigational candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

Copyright © Endeavor BioMedicines

Copyright © Endeavor BioMedicines